Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 76

Similar articles for PubMed (Select 17608729)

1.

TACE: a new target in epidermal growth factor receptor dependent tumors.

Kenny PA.

Differentiation. 2007 Nov;75(9):800-8. Epub 2007 Jul 2. Review.

PMID:
17608729
2.

Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer.

Rego SL, Helms RS, Dréau D.

Immunol Res. 2014 Jan;58(1):87-100. doi: 10.1007/s12026-013-8434-7. Review.

PMID:
24072428
3.

TACE-dependent TGFα shedding drives triple-negative breast cancer cell invasion.

Giricz O, Calvo V, Peterson EA, Abouzeid CM, Kenny PA.

Int J Cancer. 2013 Dec 1;133(11):2587-95. doi: 10.1002/ijc.28295. Epub 2013 Jun 21.

4.
5.

ADAM17, shedding, TACE as therapeutic targets.

Rose-John S.

Pharmacol Res. 2013 May;71:19-22. doi: 10.1016/j.phrs.2013.01.012. Epub 2013 Feb 13. Review.

PMID:
23415892
6.

The role of ADAM17 in metabolic inflammation.

Menghini R, Fiorentino L, Casagrande V, Lauro R, Federici M.

Atherosclerosis. 2013 May;228(1):12-7. doi: 10.1016/j.atherosclerosis.2013.01.024. Epub 2013 Jan 25. Review.

PMID:
23384719
7.

Targeting G protein and phosphorylation dependent signalling molecules for anticancer therapy.

Eswaran J.

Anticancer Agents Med Chem. 2012 Jan;12(1):2-3. No abstract available.

PMID:
22320243
8.

Biaryl substituted hydantoin compounds as TACE inhibitors.

Yu W, Tong L, Kim SH, Wong MK, Chen L, Yang DY, Shankar BB, Lavey BJ, Zhou G, Kosinski A, Rizvi R, Li D, Feltz RJ, Piwinski JJ, Rosner KE, Shih NY, Siddiqui MA, Guo Z, Orth P, Shah H, Sun J, Umland S, Lundell DJ, Niu X, Kozlowski JA.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5286-9. doi: 10.1016/j.bmcl.2010.06.134. Epub 2010 Jul 1.

PMID:
20663669
9.

ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer?

Lee AM, Diasio RB.

Clin Cancer Res. 2010 Jul 1;16(13):3319-21. doi: 10.1158/1078-0432.CCR-10-1059. Epub 2010 Jun 22.

10.

Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer.

Kyula JN, Van Schaeybroeck S, Doherty J, Fenning CS, Longley DB, Johnston PG.

Clin Cancer Res. 2010 Jul 1;16(13):3378-89. doi: 10.1158/1078-0432.CCR-10-0014. Epub 2010 Jun 22.

11.

ADAM-17: the enzyme that does it all.

Gooz M.

Crit Rev Biochem Mol Biol. 2010 Apr;45(2):146-69. doi: 10.3109/10409231003628015. Review.

12.

Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.

Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E, Cercignani G, Orlandini E, Nencetti S, Rossello A.

J Med Chem. 2010 Mar 25;53(6):2622-35. doi: 10.1021/jm901868z.

PMID:
20180536
13.

Discovery and SAR of hydantoin TACE inhibitors.

Yu W, Guo Z, Orth P, Madison V, Chen L, Dai C, Feltz RJ, Girijavallabhan VM, Kim SH, Kozlowski JA, Lavey BJ, Li D, Lundell D, Niu X, Piwinski JJ, Popovici-Muller J, Rizvi R, Rosner KE, Shankar BB, Shih NY, Siddiqui MA, Sun J, Tong L, Umland S, Wong MK, Yang DY, Zhou G.

Bioorg Med Chem Lett. 2010 Mar 15;20(6):1877-80. doi: 10.1016/j.bmcl.2010.01.148. Epub 2010 Feb 4.

PMID:
20172725
14.

Novel TACE inhibitors in drug discovery: a review of patented compounds.

Murumkar PR, DasGupta S, Chandani SR, Giridhar R, Yadav MR.

Expert Opin Ther Pat. 2010 Jan;20(1):31-57. doi: 10.1517/13543770903465157. Review.

PMID:
20021284
15.

EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments.

Kataoka H.

J Dermatol Sci. 2009 Dec;56(3):148-53. doi: 10.1016/j.jdermsci.2009.10.002. Epub 2009 Nov 6. Review.

PMID:
19896805
16.

ADAM17 as a therapeutic target in multiple diseases.

Arribas J, Esselens C.

Curr Pharm Des. 2009;15(20):2319-35. Review.

PMID:
19601834
17.

Release of soluble tumor necrosis factor receptor 1 from corneal epithelium by TNF-alpha-converting enzyme-dependent ectodomain shedding.

Sakimoto T, Yamada A, Sawa M.

Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4618-21. doi: 10.1167/iovs.08-2669. Epub 2009 Apr 30.

PMID:
19407014
18.

Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands.

Nakagawa M, Nabeshima K, Asano S, Hamasaki M, Uesugi N, Tani H, Yamashita Y, Iwasaki H.

Cancer Sci. 2009 Apr;100(4):654-62. doi: 10.1111/j.1349-7006.2009.01089.x. Epub 2009 Mar 1.

PMID:
19298600
19.

Role of ADAMs in cancer formation and progression.

Duffy MJ, McKiernan E, O'Donovan N, McGowan PM.

Clin Cancer Res. 2009 Feb 15;15(4):1140-4. doi: 10.1158/1078-0432.CCR-08-1585. Review.

20.

Removal of cell surface heparan sulfate increases TACE activity and cleavage of ErbB4 receptor.

Määttä JA, Olli K, Henttinen T, Tuittila MT, Elenius K, Salmivirta M.

BMC Cell Biol. 2009 Jan 26;10:5. doi: 10.1186/1471-2121-10-5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk